Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S; AMBER and EMERALD Study Groups. Lathouwers E, et al. AIDS Res Hum Retroviruses. 2020 Jan;36(1):48-57. doi: 10.1089/AID.2019.0111. Epub 2019 Oct 21. AIDS Res Hum Retroviruses. 2020. PMID: 31516033 Free PMC article. Clinical Trial.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). ...All achie …
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, …
Reporting checklist for foundation and large language models in medical research (REFINE): an international consensus guideline.
Mese I, Akinci D'Antonoli T, Bluethgen C, Bressem K, Cuocolo R, Chaudhari A, Tejani AS, Isaac A, Ponsiglione A, Meddeb A, Khosravi B, Le Guellec B, Kahn CE Jr, Suh CH, Pinto Dos Santos D, Koh DM, Tzanis E, Kotter E, Colak E, Kitamura F, Busch F, Nensa F, Yang G, Müller H, Kather JN, Nawabi J, Kleesiek J, Zhong J, Santinha J, Haubold J, de Almeida JG, Lekadir K, Marias K, Reiner LN, Maier-Hein L, Moy L, Adams LC, Martí-Bonmatí L, Paschali M, Moassefi M, Dietzel M, Huisman M, Ingrisch M, Klontzas ME, Papanikolaou N, Diaz O, Kuriki P, Seeböck P, Rouzrokh P, Strotzer QD, Park SH, Faghani S, Tayebi Arasteh S, Kim SH, Venugopal VK, Kim W, Kocak B. Mese I, et al. Diagn Interv Radiol. 2026 Feb 26. doi: 10.4274/dir.2026.263812. Online ahead of print. Diagn Interv Radiol. 2026. PMID: 41742713 Free article.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masiá M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Rizzardini G, et al. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466. J Acquir Immune Defic Syndr. 2020. PMID: 33136751 Free PMC article. Clinical Trial.
Implementing a Psychosocial Screener in Pediatric Oncology: Perspectives of Multidisciplinary Clinicians.
Paeps M, Scialla MA, Barakat LP, Arasteh K, Kazak AE. Paeps M, et al. Psychooncology. 2025 Dec;34(12):e70356. doi: 10.1002/pon.70356. Psychooncology. 2025. PMID: 41413391

PIQ-B had a significantly lower mean score (M = 2.03) than PIQ-F (M = 3.08), p < 0.001). Barriers and facilitators rated most impactful (highest mean scores) were: Barriers: "Language barriers/cultural considerations" (M = 2.37) and "Integrating results in EHR" (M = 2.2

…

PIQ-B had a significantly lower mean score (M = 2.03) than PIQ-F (M = 3.08), p < 0.001). Barriers and facilitators rated most impa

…